Open an account

Emergent BioSolutions

EBS · NYSE

$6.29−$0.07 (−1.10%)TodayMarket closed ·
Prev close $6.36

EBS analyst rating

HoldConsensus of 2 analysts over the last 12 months. 50% rate it a buy.
  • Strong buy0
  • Buy1
  • Hold0
  • Underperform1
  • Sell0

12-month price target · 3 analysts

Average $11.22 (+78.4% upside)

Low
$10.10
Now
$6.29
High
$12.60

Upgrades and downgrades

The latest rating actions, newest first

EBS analyst upgrades, downgrades and rating actions
FirmDateActionRating
HC Wainwright & Co.Sep 9, 2026MaintainsBuy
JP MorganAug 21, 2026InitiatesUnderweight
HC Wainwright & Co.Aug 10, 2026MaintainsBuy
HC Wainwright & Co.Mar 9, 2026MaintainsBuy
HC Wainwright & Co.Dec 16, 2025MaintainsBuy

The case for and against

Updated Oct 16, 2026

Bull case

Emergent BioSolutions is viewed positively because it is actively strengthening its balance sheet through a $75 million repurchase of 3.875% senior unsecured notes, using about $68 million of cash and cutting the notes balance to roughly $364.7 million while preserving liquidity above $180 million of cash and access to an additional $50 million under its revolving facility. Its government-focused franchise also appears durable, supported by a ~$24 million BARDA contract for CYFENDUS and an earlier delivery order of up to $21.5 million for BioThrax, alongside commercial momentum from NARCAN, ACAM2000, and related approvals. In addition, the restructuring plan targeting approximately $40 million of annualized cost savings after about $10 million of charges, plus a streamlined growth organization, should improve efficiency and support earnings resilience.

Bear case

Emergent BioSolutions is facing a weakening fundamental profile as NARCAN franchise erosion accelerates, with 2Q26 sales down 22% year over year and full-year 2026 revenue guidance cut to $645M-$675M from $720M-$760M. The deterioration is being driven by higher generic and OTC competition from REXTOVY and REZENOPY, which is expected to keep pressuring the company’s largest U.S. revenue stream despite ongoing opioid-related demand. The outlook is further constrained by dependence on uncertain MCM government contracts, approval risk for key products, and possible medium- to long-term dilution risk, all of which support a bearish view under the DCF framework.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.